DRAGARWQ5,301.00

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth+24.4+18.6
EBITDA Growth+30.1+22.6
EBIT Growth+22.7+26.1
Net Income Growth+17.9+28.3
EPS Growth+17.9+26.4
Total Assets Growth+23.7+25.0
Total Equity Growth+33.4+65.2
Cash from Operations Growth+5.2
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.